About
PerSimiO offers a superior prediction technology based on proprietary simulation of the response of human bones to load. The technology has been validated by ex-vivo experiments on a large cohort of human femurs, using routine CT scans. PerSimiO's patented technology is a fully automated web-service that may be integrated within a hospital PACS or accessed from a web-browser as a locally hosted web-application.
Although the team has applied the technology primarily to femur-related conditions, it plans to expand the list of Simfini applications to assess bone strength in the humerus, vertebrae, and other bones of the body. The company's products target the diagnosis and treatment of a variety of diseases including osteoporosis, metastatic tumors, and injuries that weaken the bone. The products are designed to optimize treatment and improve outcomes at a reduced cost.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is PerSimiO's primary focus and what technology do they utilize?
- PerSimiO focuses on predicting fracture risk for patients with cancer and osteoporosis. They utilize a proprietary simulation technology to predict the response of human bones to load, which has been validated by ex-vivo experiments using routine CT scans.
- When was PerSimiO founded and where is its headquarters located?
- PerSimiO was founded in January 2015 and is headquartered in Be'er Sheva, Israel, at HaEnergia Street 77.
- What is the total amount of grant funding PerSimiO has received, and from which grantor?
- PerSimiO has received a total of $955,000 in grants from the IIA. This includes a $529,000 grant in October 2015 and a $426,000 grant in August 2017.
- What is the current employee count for PerSimiO?
- PerSimiO currently has 9 employees.
- What are the key products offered by PerSimiO?
- PerSimiO offers several products under the 'Simfini' line, including Simfini-TUMOR, Simfini-IMPLANT, Simfini-OSTEO, Simfini-DIABETES, and Simfini-SENIOR.
- What is the current product stage for PerSimiO's offerings?
- PerSimiO's products are currently in the clinical trial stage.
- What is the primary sector PerSimiO operates in?
- PerSimiO's primary sector is Health Tech & Life Sciences.
- What is PerSimiO's patented technology?
- PerSimiO's patented technology is a fully automated web-service that can be integrated within a hospital PACS or accessed as a locally hosted web-application from a web-browser. It is based on a CT-based prediction model to simulate the response of human bones to load.